Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such as the rise of neuro-immunology and the industry’s embrace of digital health tools to support drug development in a recent interview.
The partnership is a win for Fitchet’s plan to turn around J&J’s slow-growing device unit by partnering with external players.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Also, a court awarded a woman $55 million after concluding that her ovarian cancer was linked to the use of Johnson & Johnson's talc powder products and Beth Israel Deaconess is taking on the issue of patient death in hospitals and how errors can be avoided.
The shift by Johnson & Johnson (NYSE: JNJ) to provide Yale University School of Medicine’s Open Data Access Project with de-identified data from clinical trials, conceived over a conversation between two Harvard Medical School classmates going for a walk, has huge ramifications for research scientists and patient groups. It also reflects a big change in […]
Despite a major setback last summer when its promising drug bapineuzumab failed in late-stage clinical trials, Janssen Pharmaceuticals is looking to beef up its Alzheimer’s disease drug pipeline in a new deal with Evotec AG. Drug discovery company Evotec has a proprietary database of genes that are dysregulated in Alzheimer’s patients, as discovered in the […]
A group of 10 big pharma companies are collaborating in a move that could change the way clinical trials are done. One goal of the nonprofit will be to provide better information on the risks and benefits of drugs and therapeutics more efficiently, according to a company statement. TransCelerate BioPharma, based in Philadelphia, will involve […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In a move to gain access to early stage innovation, Johnson & Johnson (NYSE:JNJ) is opening innovation centers in Europe and China as well as in Boston. Earlier this year, its Janssen pharmaceuticals division opened an innovation center within the company’s West Coast Research Center in San Diego. The centers will be staffed with J&J […]
One theory behind improving patient adherence is it’s a question of memory and helping people stay better organized. For people who may be taking several medications at once, missing one or two medication times can lessen the effect of the drug, or negatively impact the person’s health. Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Healthcare […]
The U.S. Food and Drug Administration has declined to approve Johnson & Johnson (NYSE:JNJ) drug Xarelto to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome, such as myocardial infarction and stroke, until questions raised by the regulator are addressed. The news follows an FDA committee move last month to recommend […]
Janssen, a division of Johnson & Johnson (NYSE:JNJ) has submitted a new drug application for canagliflozin that belongs to a new class of drugs called SGLT2 inhibitors to treat type 2 diabetes. The drugmaker is surely hoping it fares better than its rivals AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb (NYSE:BMY) since the U.S. Food and Drug […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
A Johnson & Johnson (NYSE:JNJ) division for the company’s tampon, lubricant and dental floss business has drawn heat from the U.S. Food and Drug Administration over its handling of medical complaints and failing to comply with good manufacturing practices. According to the warning letter issued May 22, McNeil-PPC adulterated its K-Y Jelly and other K-Y […]
An application for a higher dosage of an FDA-approved HIV drug from Janssen Pharmaceuticals has been turned down by the U.S. Food and Drug Administration, according to a company statement. The complete response letter was for an 800 milligram dose of Prezista, a protease inhibitor. The Titusville, New Jersey company, the Pharmaceutical Division of Johnson […]
Johnson and Johnson’s (NYSE:JNJ) CEO Alex Gorsky is apparently shopping around for medical device companies to boost sagging sales in its Cardiovascular Division. A Bloomberg story highlights how some analysts believe companies like St. Jude Medical and Edwards Lifesciences could be good acquisition targets. J&J’s strategy of growing through acquisitions appears to contrast with the […]
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson’s (NYSE: JNJ) antibiotic Levaquin against pneumonic plague in the event of a bioterrorist attack through its rarely invoked animal rule, according to a statement from the U.S. regulator. The animal efficacy rule allows evidence to support a drug’s approval to […]
Despite encouraging sales performance in the first quarter for recently approved oncology drugs, Johnson & Johnson (NYSE:JNJ) continues to be vexed by manufacturing problems. That, coupled with new questions over its incoming CEO, paint a mixed picture for how 2012 will shake out for the pharmaceutical and medical device giant. A consent decree from the […]